Literature DB >> 22648049

Detection of non-alcoholic steatohepatitis in patients with morbid obesity before bariatric surgery: preliminary evaluation with acoustic radiation force impulse imaging.

F Guzmán-Aroca1, M D Frutos-Bernal, A Bas, J A Luján-Mompeán, M Reus, Juan de Dios Berná-Serna, P Parrilla.   

Abstract

OBJECTIVE: To investigate the utility of acoustic radiation force impulse (ARFI) imaging, with the determination of shear wave velocity (SWV), to differentiate non-alcoholic fatty liver disease (NAFLD) from non-alcoholic steatohepatitis (NASH) in patients with morbid obesity before bariatric surgery.
METHODS: Thirty-two patients with morbid obesity were evaluated with ARFI and conventional ultrasound before bariatric surgery. The ARFI and ultrasound results were compared with liver biopsy findings, which is the reference standard. The patients were classed according to their histological findings into three groups: group A, simple steatosis; group B, inflammation; and group C, fibrosis.
RESULTS: The median SWV was 1.57 ± 0.79 m/s. Hepatic alterations were observed in the histopathological findings for all the patients in the study (100 %), with the results of the laboratory tests proving normal. Differences in SWV were also observed between groups A, B and C: 1.34 ± 0.90 m/s, 1.55 ± 0.79 m/s and 1.86 ± 0.75 m/s (P < 0.001), respectively. The Az for differentiating NAFLD from NASH or fibrosis was 0.899 (optimal cut-off value 1.3 m/s; sensitivity 85 %; specificity 83.3 %).
CONCLUSION: The ARFI technique is a useful diagnostic tool for differentiating NAFLD from NASH in asymptomatic patients with morbid obesity. KEY POINTS : • Acoustic radiation force impulse imaging provides ultrasonic shear wave velocity measurements. • SWV measurements were higher in patients with inflammation or fibrosis than NAFLD. • ARFI differentiates NAFLD from NASH in patients with morbid obesity. • Results suggest that ARFI can detect NASH in asymptomatic morbidly obese patients.

Entities:  

Mesh:

Year:  2012        PMID: 22648049     DOI: 10.1007/s00330-012-2505-3

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  31 in total

Review 1.  Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group.

Authors:  John McHutchison; Thierry Poynard; Nezam Afdhal
Journal:  Clin Gastroenterol Hepatol       Date:  2006-09-18       Impact factor: 11.382

2.  Reproducibility of shear wave velocity measurements by acoustic radiation force impulse imaging of the liver: a study in healthy volunteers.

Authors:  Florentina Guzmán-Aroca; Manuel Reus; Juan D Berná-Serna; Laura Serrano; Cristina Serrano; Amparo Gilabert; Angela Cepero
Journal:  J Ultrasound Med       Date:  2011-07       Impact factor: 2.153

3.  Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography.

Authors:  Masato Yoneda; Kaori Suzuki; Shingo Kato; Koji Fujita; Yuichi Nozaki; Kunihiro Hosono; Satoru Saito; Atsushi Nakajima
Journal:  Radiology       Date:  2010-06-07       Impact factor: 11.105

4.  The disease burden associated with overweight and obesity.

Authors:  A Must; J Spadano; E H Coakley; A E Field; G Colditz; W H Dietz
Journal:  JAMA       Date:  1999-10-27       Impact factor: 56.272

Review 5.  Sonographic diagnosis of diffuse liver disease.

Authors:  W J Zwiebel
Journal:  Semin Ultrasound CT MR       Date:  1995-02       Impact factor: 1.875

6.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Authors:  Laurent Castéra; Julien Vergniol; Juliette Foucher; Brigitte Le Bail; Elise Chanteloup; Maud Haaser; Monique Darriet; Patrice Couzigou; Victor De Lédinghen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

7.  Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease.

Authors:  Mark L Palmeri; Michael H Wang; Ned C Rouze; Manal F Abdelmalek; Cynthia D Guy; Barry Moser; Anna Mae Diehl; Kathryn R Nightingale
Journal:  J Hepatol       Date:  2011-01-21       Impact factor: 25.083

8.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

9.  The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis.

Authors:  Anneloes E Bohte; Jochem R van Werven; Shandra Bipat; Jaap Stoker
Journal:  Eur Radiol       Date:  2010-07-31       Impact factor: 5.315

Review 10.  Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease.

Authors:  Francesco Vizzutti; Umberto Arena; Valerio Nobili; Roberto Tarquini; Marco Trappoliere; Giacomo Laffi; Fabio Marra; Massimo Pinzani
Journal:  Ann Hepatol       Date:  2009 Apr-Jun       Impact factor: 2.400

View more
  17 in total

Review 1.  Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 2.  Liver elastography, comments on EFSUMB elastography guidelines 2013.

Authors:  Xin-Wu Cui; Mireen Friedrich-Rust; Chiara De Molo; Andre Ignee; Dagmar Schreiber-Dietrich; Christoph F Dietrich
Journal:  World J Gastroenterol       Date:  2013-10-14       Impact factor: 5.742

Review 3.  JSUM ultrasound elastography practice guidelines: liver.

Authors:  Masatoshi Kudo; Tsuyoshi Shiina; Fuminori Moriyasu; Hiroko Iijima; Ryosuke Tateishi; Norihisa Yada; Kenji Fujimoto; Hiroyasu Morikawa; Masashi Hirooka; Yasukiyo Sumino; Takashi Kumada
Journal:  J Med Ultrason (2001)       Date:  2013-08-16       Impact factor: 1.314

4.  Cost-utility analysis of nonalcoholic steatohepatitis screening.

Authors:  Eric Zhang; Claire Wartelle-Bladou; Luigi Lepanto; Jean Lachaine; Guy Cloutier; An Tang
Journal:  Eur Radiol       Date:  2015-05-21       Impact factor: 5.315

Review 5.  Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel.

Authors:  Jeanne M Horowitz; Sudhakar K Venkatesh; Richard L Ehman; Kartik Jhaveri; Patrick Kamath; Michael A Ohliger; Anthony E Samir; Alvin C Silva; Bachir Taouli; Michael S Torbenson; Michael L Wells; Benjamin Yeh; Frank H Miller
Journal:  Abdom Radiol (NY)       Date:  2017-08

Review 6.  Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions.

Authors:  Paul Kennedy; Mathilde Wagner; Laurent Castéra; Cheng William Hong; Curtis L Johnson; Claude B Sirlin; Bachir Taouli
Journal:  Radiology       Date:  2018-03       Impact factor: 11.105

Review 7.  Non-alcoholic fatty liver disease: what the clinician needs to know.

Authors:  Mariana Verdelho Machado; Helena Cortez-Pinto
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 8.  Noninvasive diagnosis of cirrhosis: a review of different imaging modalities.

Authors:  Riccardo De Robertis; Mirko D'Onofrio; Emanuele Demozzi; Stefano Crosara; Stefano Canestrini; Roberto Pozzi Mucelli
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

9.  Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study.

Authors:  Jeffrey Cui; Elhamy Heba; Carolyn Hernandez; William Haufe; Jonathan Hooker; Michael P Andre; Mark A Valasek; Hamed Aryafar; Claude B Sirlin; Rohit Loomba
Journal:  Hepatology       Date:  2015-12-18       Impact factor: 17.425

10.  Prospective assessment of liver stiffness by shear wave elastography in childhood obesity: a pilot study.

Authors:  Domenico Corica; Antonio Bottari; Tommaso Aversa; Letteria Anna Morabito; Selenia Curatola; Angela Alibrandi; Giorgio Ascenti; Malgorzata Wasniewska
Journal:  Endocrine       Date:  2021-07-23       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.